◆英語タイトル:Recipharm AB - Strategic SWOT Analysis Review
◆商品コード:GDPH133157SA
◆発行会社(調査会社):
GlobalData
◆発行日:2021年4月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Recipharm AB – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company’s manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services supports customers from initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel and the US. Recipharm is headquartered in Stockholm, Sweden.
Recipharm AB Key Recent Developments
Mar 02,2021: Recipharm names 2020 International Environmental Award winner
Feb 10,2021: Recipharm bolsters biologics offering
Jan 28,2021: Recipharm publishes report for the fourth quarter and full year 2020
Dec 09,2020: Recipharm invests USD 2.5 million in clinical GMP capacity for active pharmaceutical ingredients
Nov 10,2020: Recipharm invests in its pMDI valves production capacity
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Recipharm AB – Key Facts
Recipharm AB – Key Employees
Recipharm AB – Key Employee Biographies
Recipharm AB – Major Products and Services
Recipharm AB – History
Recipharm AB – Company Statement
Recipharm AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB – Business Description
Business Segment: ADS
Overview
Performance
Business Segment: D&L
Overview
Performance
Business Segment: MFG-S
Overview
Performance
Business Segment: MFG-SO
Overview
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: India
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Portugal
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Recipharm AB – Corporate Strategy
Recipharm AB – SWOT Analysis
SWOT Analysis – Overview
Recipharm AB – Strengths
Recipharm AB – Weaknesses
Recipharm AB – Opportunities
Recipharm AB – Threats
Recipharm AB – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Recipharm AB, Recent Deals Summary
Section 4 – Company’s Recent Developments
Mar 02, 2021: Recipharm names 2020 International Environmental Award winner
Feb 10, 2021: Recipharm bolsters biologics offering
Jan 28, 2021: Recipharm publishes report for the fourth quarter and full year 2020
Dec 09, 2020: Recipharm invests USD 2.5 million in clinical GMP capacity for active pharmaceutical ingredients
Nov 10, 2020: Recipharm invests in its pMDI valves production capacity
Nov 05, 2020: Recipharm publishes its interim report for the third quarter 2020
Oct 13, 2020: Recipharm invests EUR 2.6 million in Kaysersberg facility
Jul 27, 2020: Recipharm publishes its interim report for the second quarter 2020
Jul 13, 2020: Recipharm doubles EBIT and expects second quarter results to be stronger than analyst consensus
May 07, 2020: Recipharm publishes its interim report January-March 2020
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Recipharm AB, Recent Deals Summary